Equities

Kaken Pharmaceutical Co Ltd

Kaken Pharmaceutical Co Ltd

Actions
  • Price (USD)28.00
  • Today's Change0.00 / 0.00%
  • Shares traded1.58k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 09 2024 14:38 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Kaken Pharmaceutical Co Ltd had relatively flat revenues (72.98bn to 72.04bn), though the company grew net income 47.54% from 5.44bn to 8.03bn.
Gross margin53.41%
Net profit margin10.08%
Operating margin11.37%
Return on assets4.25%
Return on equity5.20%
Return on investment4.88%
More ▼

Cash flow in JPYView more

In 2024, cash reserves at Kaken Pharmaceutical Co Ltd fell by 8.94bn. However, the company earned 2.58bn from its operations for a Cash Flow Margin of 3.58%. In addition the company used 5.85bn on investing activities and also paid 5.66bn in financing cash flows.
Cash flow per share265.25
Price/Cash flow per share17.92
Book value per share3,763.43
Tangible book value per share3,568.11
More ▼

Balance sheet in JPYView more

Kaken Pharmaceutical Co Ltd appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio4.72
Quick ratio3.98
Total debt/total equity0.027
Total debt/total capital0.0263
More ▼

Growth rates in JPY

SmartText is unavailable
Div yield(5 year avg)3.74%
Div growth rate (5 year)0.00%
Payout ratio (TTM)78.20%
EPS growth(5 years)-13.76
EPS (TTM) vs
TTM 1 year ago
42.86
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.